Investment Thesis
Solid Biosciences exhibits critical financial distress with collapsing revenue (-40.6% YoY), unsustainable operating losses of $179.2M against only $8.1M in revenue, and severe cash burn of $157.4M annually that will exhaust the company's $59.9M cash reserve in approximately 4 months. Without immediate capital raise or dramatic operational restructuring, the company faces existential liquidity crisis.
Strengths
- Strong balance sheet with $180M stockholders' equity and zero long-term debt, preserving financial flexibility for capital raises
- Excellent liquidity ratios (6.14x current/quick ratio) ensuring near-term operational continuity
- EPS improved 35% YoY, showing some moderation in per-share losses despite deteriorating operations
Risks
- Critical cash runway: $59.9M cash against $156.3M annual operating burn leaves only 4-5 months of liquidity at current rate
- Revenue collapse of 40.6% YoY signals severe business deterioration, failed product commercialization, or pipeline failure
- Extreme operating losses (-$179.2M) with operating margin of -2214% indicate fundamental business model dysfunction and unsustainable cost structure
Key Metrics to Watch
- Quarterly cash balance and burn rate trajectory to determine capital raise timing and dilution magnitude
- Revenue stabilization and new product/pipeline catalysts to validate business viability
- Operating expense reduction initiatives and path to operating cash flow positive status
Financial Metrics
Revenue
8.1M
Net Income
-174.3M
EPS (Diluted)
$-1.99
Free Cash Flow
-157.4M
Total Assets
232.5M
Cash
59.9M
Profitability Ratios
Gross Margin
N/A
Operating Margin
-2,214.1%
Net Margin
-2,153.8%
ROE
-96.8%
ROA
-75.0%
FCF Margin
-1,945.2%
Balance Sheet & Liquidity
Current Ratio
6.14x
Quick Ratio
6.14x
Debt/Equity
0.00x
Debt/Assets
22.6%
Interest Coverage
-979.27x
Long-term Debt
N/A
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-04-16T00:42:29.505336 |
Data as of: 2025-12-31 |
Powered by Claude AI